Connor E. Gould

Connor E. Gould

Auto-generated profile, based on publicly available information

Connor E. Gould

University at Buffalo

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2026 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
RDRobin DiFrancesco
Robin DiFrancesco
Troy Dale WoodTroy Dale Wood
Troy Dale Wood
RCRaymond Cha
Raymond Cha
JHJill S. Hochreiter
Jill S. Hochreiter
SRSusan L. Rosenkranz
Susan L. Rosenkranz
GMGene D. Morse
Gene D. Morse
When the acquired immunodeficiency syndrome emerged in the 1980s, the United States National Institutes of Health established research networks to conduct clinical trials with the pharmaceutical industry to identify effective antiretroviral therapeutics. The clinical trials networks included laboratory centers with academic pharmacology laboratories measuring drug concentrations to allow for the estimation of pharmacokinetic parameters and correlation with pharmacodynamic outcomes. Adoption of comprehensive quality assurance initiatives was key to ensuring the integrity of pharmacology sampling and laboratory data provided by clinical sites and laboratories. Subsequently, this infrastructure facilitated rapid responses to co‐infection pathogens such as hepatitis C virus, Mycobacterium tuberculosis, and severe acute respiratory syndrome coronavirus 2. In 2008, the Center for Integrated Global Biomedical Sciences at the University at Buffalo was awarded the initial National Institute of Allergy and Infectious Diseases contract for the Clinical Pharmacology Quality Assurance Program. Since 2015, over 4,500 tutorial certificates for research staff and laboratories have been awarded on topics including the conduct of clinical pharmacology research protocols and bioanalytical method validation for antiretroviral assays. A bioanalytical peer review program for ensuring the quality of the assay methods has approved over 350 assays for > 100 analytes in 21 human biological matrices. An ISO‐17043 accredited external proficiency testing program has completed 35 rounds for 15 analytes. Also, a laboratory assessment program was established that utilizes international laboratory and regulatory standards, and multiple mechanisms for training, assistance and guidance to participants. This report summarizes the development of the CPQA program over the last decade.

1 January 2026
Verified
Book Chapter
Closed access
PDF file
CGConnor E. Gould
Connor E. Gould
AEAlhaji Simon Ekere
Alhaji Simon Ekere
TNThomas D. Nguyen
Thomas D. Nguyen
JSJacob T. Sanborn
Jacob T. Sanborn
LCLiang Chen
Liang Chen
Troy Dale WoodTroy Dale Wood
Troy Dale Wood

29 May 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
TNThomas D. Nguyen
Thomas D. Nguyen
CGConnor E. Gould
Connor E. Gould
JSJacob T. Sanborn
Jacob T. Sanborn
JTJoshua Tutin
Joshua Tutin
YPYan Pan
Yan Pan
NSNicholas Smith
Nicholas Smith
Bacteriophages are a promising therapeutic class against drug-resistant bacterial infections but require analytical methods meeting modern drug development standards. Plaque-based enumeration, the gold standard, is laborious, host-dependent, and highly variable. Targeted mass spectrometry of virion structural proteins offers an orthogonal, host-independent, scalable alternative. Here, we describe a targeted proteomic LC-MS/MS assay for the Pseudomonas aeruginosa podovirus LUZ19. Peptide mapping identified multiple structural proteins, providing 55% sequence coverage of a LUZ19 major capsid protein, from which the signature peptide EVAELDGQELAR was selected for quantitation. Using multiple reaction monitoring, calibrators and quality controls were evaluated across three independent runs, with calibrator bias of −7.0 to 4.6%, intra-day precision of 0.5 to 9.3%, and inter-day precision of 6.6 to 12.0%. Peptide concentrations were related to plaque-assay titers by weighted Deming regression, yielding an empirical copy number of 1,314 (95% CI: 1,098 to 1,529) peptide copies per PFU and a phage-equivalent concentration. This proof-of-concept study establishes the analytical foundation for a fully validated assay.